SPEAKERS

Alexandros Patsilinakos

Head of Medicinal Chemistry

Sibylla Biotech

Andrea Testa

Senior Director Discovery Chemistry

Amphista Therapeutics

Andreas Mantoulidis

Research Laboratory Head

Boehringer Ingelheim

Andrew Potterton

Chief Technology Officer

Ternary Therapeutics

Andy Pike

Project leader, DMPK, Oncology R&D

AstraZeneca

Arnout Schepers

CEO

TenAces Biosciences

Benedict Cross

Chief Technology Officer & Head of Platform

PhoreMost

Chinatsu Sakata-Sakurai

Vice President, Primary Focus Lead, Targeted Protein Degradation, Astellas

Astellas Pharma

Chris Tame

Co-Founder, Chief Executive Officer

Ternary Therapeutics

Gali Prag

Co-Founder

Coltac Therapeutics

Giovanni Spagnolli

Chief Technology Officer

Sibylla Biotech

Heide Duevel

PROTAC Technology Platform Lead

Merck Healthcare KGaA

Ian Storer

Head of Hit Discovery

AstraZeneca

Kevin Wilson

Vice President & Head of Chemistry

Foghorn Therapeutics

Kurt Pike

Senior Director - External Innovation

Johnson & Johnson

Luc Brunsveld

Professor | Co-Founder

Technical University of Eindhoven | Ambagon Therapeutics

Luca Naef

Co-Founder & Chief Technology Officer

VantAI

Markus Queisser

Scientific Director

GlaxoSmithKline

Matthias Brand

Chief Scientific Officer

Proxygen

Maureen Galmes-Spit

Vice President - Research

Laigo Bio

Peggy Scherle

Chief Scientific Officer

Prelude Therapeutics​

Randolph Lopez

Co-founder & Chief Technology Officer

A-Alpha Bio Inc.

Rick Ewing

Vice President & Head of Chemistry

Rapafusyn Pharmaceuticals

Simon Glerup

Chief Scientific Officer

Draupnir Bio Aps

Vivek Vishnudas

Chief Technology Officer

BPGBio Inc.

William Mcewan

Fellow

Cambridge University

Zhangping Xiao

Marie Curie Fellow Postdoc, Tate Group

Imperial College London

Zoran Rankovic

Director & Professor - Chemical Biology & Protein Degradation

Institute of Cancer Research

REGISTER
PARTNER